RxDoctor Payments Data

George Andrews, MD

Interventional Pain Medicine · Warren, OHNPI 1861667370

Payments from drug & device makers

What this record shows

Vertiflex, Inc. accounts for 61.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $2,639 and has fallen 79.7% since, to $537 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in OH, where the typical reported total is $5,193.

$3,697in general payments, 2019–2025

Across 41 payments — averaging $90.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertiflex, Inc.$2K
  • Globus Medical$347
  • Boston Scientific$298
  • Vertos Medical, Inc.$197
  • Medtronic$134
  • Flowonix Medical Incorporated$115
  • plus $336 from 11 others

What the payments were for

  • Travel & lodging$1,92352%
  • Food & beverage$1,77448%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,697 in reported general payments places this provider in the 40th percentile of 67 interventional pain medicine providers in Ohio.

See all interventional pain medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$191,234
Medicare patients
234
Services billed
4,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen715$20,742
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen774$18,684
Xtampza ErOxycodone Myristate41$17,931
Buprenorphine57$13,688
Gabapentin662$11,575
Tramadol Hcl ErTramadol Hcl156$10,837
Pregabalin232$5,149
Tizanidine Hcl456$3,813
Duloxetine Hcl247$2,730
Naloxone Hcl31$2,095
Tramadol Hcl220$2,073
Cyclobenzaprine Hcl193$1,939
Methocarbamol161$1,409
Lidocaine25$1,231
Fentanyl12$1,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$12$17,93141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 67 interventional pain medicine providers in Ohio.

Other interventional pain medicine in Warren

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →